Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intelligent Bio Solutions ( (INBS) ) has provided an announcement.
Intelligent Bio Solutions Inc. has released the initial results of its Pharmacokinetic study necessary for an FDA 510(k) submission, which can now be viewed on their website. The company successfully raised approximately $250,802 through a strategic sale of common stock, capitalizing on their At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc., showcasing their financial growth and investment potential.
For detailed information about INBS stock, go to TipRanks’ Stock Analysis page.